Skip to main content
logo
Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
535.27
+19.93 (3.87%)
At close: Aug 11, 2026, 4:00 PM EDT
539.00
+3.73 (0.70%)
Pre-market: Aug 12, 2026, 9:15 AM EDT

Madrigal Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
1,284958.4180.13---
Revenue Growth
149.04%432.05%----
Cost of Revenue
109.4256.156.23---
Gross Profit
1,175902.26173.9---
Selling, General & Admin
1,007813.83435.06108.1548.1337.32
Research & Development
490.14388.53236.72272.35245.44205.16
Total Operating Expenses
1,4971,202671.78380.5293.57242.48
Operating Income
-322.62-300.1-497.88-380.5-293.57-242.48
Interest Income
35.1137.3646.6519.582.190.36
Interest Expense
-31.51-22.31-14.67-12.71-3.96-
Other Non-Operating Income (Expense)
-3.31-3.24---0.27
Total Non-Operating Income (Expense)
0.311.8131.986.87-1.780.64
Pretax Income
-322.32-288.28-465.89-373.63-295.35-241.85
Net Income
-325.1-288.28-465.89-373.63-295.35-241.85
Net Income to Common
-325.1-288.28-465.89-373.63-295.35-241.85
Net Income Growth
------
Shares Outstanding (Basic)
272221191717
Shares Outstanding (Diluted)
272221191717
Shares Change
9.52%5.46%13.83%9.05%3.64%7.05%
EPS (Basic)
-11.82-12.85-21.90-19.99-17.23-14.63
EPS (Diluted)
-11.82-12.85-21.90-19.99-17.23-14.63
EPS Growth
------
Free Cash Flow
-206.29-190.02-457.03-325.71-225.07-184.13
Free Cash Flow Growth
------
Free Cash Flow Per Share
-7.53-8.47-21.48-17.43-13.13-11.14
Gross Margin
91.48%94.14%96.54%---
Operating Margin
-25.13%-31.31%-276.39%---
Profit Margin
-25.32%-30.08%-258.64%---
FCF Margin
-16.07%-19.83%-253.72%---
EBITDA
-321.1-298.59-496.78-379.97-293.1-242.08
EBITDA Margin
-25.01%-31.16%-275.78%---
EBIT
-322.62-300.1-497.88-380.5-293.57-242.48
EBIT Margin
-25.13%-31.31%-276.39%---
SEC Filings: 10-K · 10-Q